JP2008507298A5 - - Google Patents

Download PDF

Info

Publication number
JP2008507298A5
JP2008507298A5 JP2007527427A JP2007527427A JP2008507298A5 JP 2008507298 A5 JP2008507298 A5 JP 2008507298A5 JP 2007527427 A JP2007527427 A JP 2007527427A JP 2007527427 A JP2007527427 A JP 2007527427A JP 2008507298 A5 JP2008507298 A5 JP 2008507298A5
Authority
JP
Japan
Prior art keywords
polypeptide
seq
conjugate
sequence
moiety
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2007527427A
Other languages
English (en)
Japanese (ja)
Other versions
JP2008507298A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2005/017471 external-priority patent/WO2005113592A2/en
Publication of JP2008507298A publication Critical patent/JP2008507298A/ja
Publication of JP2008507298A5 publication Critical patent/JP2008507298A5/ja
Pending legal-status Critical Current

Links

JP2007527427A 2004-05-19 2005-05-18 インターフェロンαポリペプチドおよび結合体 Pending JP2008507298A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US57250404P 2004-05-19 2004-05-19
PCT/US2005/017471 WO2005113592A2 (en) 2004-05-19 2005-05-18 Interferon-alpha polypeptides and conjugates

Publications (2)

Publication Number Publication Date
JP2008507298A JP2008507298A (ja) 2008-03-13
JP2008507298A5 true JP2008507298A5 (enExample) 2008-07-10

Family

ID=35428915

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2007527427A Pending JP2008507298A (ja) 2004-05-19 2005-05-18 インターフェロンαポリペプチドおよび結合体

Country Status (14)

Country Link
US (9) US7318918B2 (enExample)
EP (1) EP1753779A2 (enExample)
JP (1) JP2008507298A (enExample)
CN (1) CN101115769A (enExample)
AR (1) AR049177A1 (enExample)
AU (1) AU2005245918A1 (enExample)
BR (1) BRPI0511196A (enExample)
CA (1) CA2566247A1 (enExample)
IL (1) IL178470A0 (enExample)
MX (1) MXPA06013412A (enExample)
NO (1) NO20065084L (enExample)
RU (1) RU2006145020A (enExample)
TW (1) TW200611910A (enExample)
WO (1) WO2005113592A2 (enExample)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040005673A1 (en) * 2001-06-29 2004-01-08 Kevin Jarrell System for manipulating nucleic acids
ATE439437T1 (de) * 1999-01-05 2009-08-15 Univ Boston Verbessertes klonierungsverfahren
US7435562B2 (en) 2000-07-21 2008-10-14 Modular Genetics, Inc. Modular vector systems
US20030017552A1 (en) * 2000-07-21 2003-01-23 Jarrell Kevin A. Modular vector systems
JP2008500750A (ja) * 2004-05-12 2008-01-10 フュージョンワン インコーポレイテッド 高度な連絡先識別システム
ATE540110T1 (de) * 2004-11-11 2012-01-15 Modular Genetics Inc Oligonukleotid-leiterkonstruktion und system zur erzeugung von molekularer vielfalt
WO2006134497A2 (en) * 2005-03-09 2006-12-21 Guangwen Wei Uses of recombinant super-compound interferons
BRPI0609809A2 (pt) 2005-05-18 2011-10-11 Maxygen Inc polipeptìdeo isolado ou recombinante, conjugado, composição, polinucleotìdeo isolado ou recombinante, célula hospedeira, vetor, métodos para preparar o polipeptìdeo, para preparar um conjugado, para inibir replicação de um vìrus em células infectadas com o vìrus para reduzir o numero de cópias de um vìrus em células infectadas com o vìrus, para reduzir o nìvel de rna de hcv no soro de um paciente infectado com hcv, para reduzir o nìvel de dna de hbv em soro de um paciente infectado com hbv e para reduzir o nìvel de rna de hiv em soro de um paciente infectado com hiv, e, uso do polipeptìdeo ou do conjugado
AR078117A1 (es) * 2006-06-20 2011-10-19 Protech Pharma S A Una muteina recombinante del interferon alfa humano glicosilado, un gen que codifica para dicha muteina, un metodo de produccion de dicho gen, un metodo para obtener una celula eucariota productora de dicha muteina, un metodo para producir dicha muteina, un procedimiento para purificar dicha muteina
WO2008008808A2 (en) * 2006-07-11 2008-01-17 Modular Genetics Inc. Methods of introducing targeted diversity into nucleic acid molecules
EP2042513A4 (en) * 2006-07-25 2010-07-07 Galpharma Co Ltd Galectin-9-POLYMER CONJUGATE
US7808342B2 (en) * 2006-10-02 2010-10-05 Skyworks Solutions, Inc. Harmonic phase tuning filter for RF switches
US11535673B2 (en) 2007-04-05 2022-12-27 President and Fellows of Harvard CoHege Chimeric activators: quantitatively designed protein therapeutics and uses thereof
US7625555B2 (en) 2007-06-18 2009-12-01 Novagen Holding Corporation Recombinant human interferon-like proteins
WO2009006579A1 (en) * 2007-07-05 2009-01-08 Pharmaessentia Corp. Peptide-polymer conjugates
WO2009046080A1 (en) 2007-10-01 2009-04-09 Pharmaessentia Corp. N-terminal modified interferon-alpha
EP2245044A2 (en) * 2008-01-18 2010-11-03 F. Hoffmann-La Roche AG Purification of non-glycosylated proteins
US7954022B2 (en) * 2008-01-30 2011-05-31 Alcatel-Lucent Usa Inc. Apparatus and method for controlling dynamic modification of a scan path
AR074357A1 (es) * 2008-11-17 2011-01-12 Genentech Inc Metodo y formulacion para reducir la agregacion de una macromolecula bajo condiciones fisiologicas. metodo de dialisis in vitro
EP2391714B2 (en) 2009-01-30 2019-07-24 Whitehead Institute for Biomedical Research Methods for ligation and uses thereof
CN103747806A (zh) 2011-06-02 2014-04-23 韩美科学株式会社 非肽基聚合物-胰岛素多聚体和生产其的方法
CA2840409A1 (en) 2011-06-28 2013-01-03 Whitehead Institute For Biomedical Research Using sortases to install click chemistry handles for protein ligation
CN102358897B (zh) * 2011-10-31 2013-02-13 北京三元基因工程有限公司 重组人寡腺苷酸合成酶-1的制备方法
WO2015168474A1 (en) * 2014-04-30 2015-11-05 President And Fellows Of Harvard College Fusion proteins for treating cancer and related methods
EP3006045B3 (en) * 2014-10-07 2021-03-17 Cyprumed GmbH Pharmaceutical formulations for the oral delivery of peptide or protein drugs
IL299759A (en) 2015-12-30 2023-03-01 Genentech Inc Formulations with reduced polysorbate dissolution
DK3411398T3 (da) * 2016-02-05 2024-06-24 Orionis Biosciences BV Målrettede terapeutiske midler og anvendelse heraf
RU2650755C1 (ru) * 2017-05-24 2018-04-17 Федеральное государственное бюджетное учреждение "Государственный научный центр "Институт иммунологии" Федерального медико-биологического агентства России (ФГБУ "ГНЦ Институт иммунологии" ФМБА России) Способ очистки лекарственного средства пролонгированного действия на основе рекомбинантного аналога интерферона альфа-17 для лечения вирусного гепатита С
WO2021150674A1 (en) * 2020-01-24 2021-07-29 Alkermes, Inc. Methods of purification

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6610830B1 (en) 1980-07-01 2003-08-26 Hoffman-La Roche Inc. Microbial production of mature human leukocyte interferons
ES506955A0 (es) 1980-11-10 1983-02-01 Genentech Inc Un procedimiento para producir un polipeptido antiviral.
US4414150A (en) 1980-11-10 1983-11-08 Genentech, Inc. Hybrid human leukocyte interferons
EP0098876A1 (en) 1982-01-19 1984-01-25 Cetus Corporation Multiclass hybrid interferons
US6936694B1 (en) 1982-05-06 2005-08-30 Intermune, Inc. Manufacture and expression of large structural genes
JPS60152058A (ja) * 1984-01-20 1985-08-10 Toshiba Corp 半導体記憶装置
ATE78262T1 (de) 1985-06-11 1992-08-15 Ciba Geigy Ag Hybrid-interferone.
US4695626A (en) * 1986-07-29 1987-09-22 Pfizer Inc. 1-aza-4,5-dithiabicyclo [4.2.0] oct-2-en-8-one-2 carboxylate esters
ES2128348T3 (es) 1990-10-17 1999-05-16 Amgen Inc Obtencion de composiciones para el tratamiento de alteraciones de la proliferacion celular.
US5372808A (en) 1990-10-17 1994-12-13 Amgen Inc. Methods and compositions for the treatment of diseases with consensus interferon while reducing side effect
US5595732A (en) 1991-03-25 1997-01-21 Hoffmann-La Roche Inc. Polyethylene-protein conjugates
US5382657A (en) 1992-08-26 1995-01-17 Hoffmann-La Roche Inc. Peg-interferon conjugates
US5574138A (en) 1993-03-08 1996-11-12 Immunex Corporation Epithelium-derived T-cell factor
US6335160B1 (en) 1995-02-17 2002-01-01 Maxygen, Inc. Methods and compositions for polypeptide engineering
ATE227133T1 (de) 1994-03-07 2002-11-15 Imperial College Verwendung von interferon-alpha 8 subtype zur herstellung von medikamenten zur behandlung von viralinfektionen der leber
US5824784A (en) 1994-10-12 1998-10-20 Amgen Inc. N-terminally chemically modified protein compositions and methods
TW517067B (en) 1996-05-31 2003-01-11 Hoffmann La Roche Interferon conjugates
IL133974A0 (en) 1997-07-14 2001-04-30 Bolder Biotechnology Inc Derivatives of growth hormone and related proteins
ATE526401T1 (de) 1999-01-14 2011-10-15 Bolder Biotechnology Inc Verfahren zur herstellung von proteinen mit freien cysteinresten
AU3725600A (en) 1999-03-02 2000-09-21 Maxygen, Inc. Surrogate orphan ligands for orphan receptors
DE60035871T2 (de) 1999-05-19 2008-06-05 Merck Patent Gmbh Expression und export von interferon-alpha proteinen als fc fusionsproteine
EP1238082A2 (en) 1999-10-07 2002-09-11 Maxygen, Inc. Ifn-alpha homologues
US20040002474A1 (en) 1999-10-07 2004-01-01 Maxygen Inc. IFN-alpha homologues
IL149267A0 (en) * 1999-11-12 2002-11-10 Maxygen Holdings Ltd Interferon gamma conjugates
CN1318443C (zh) 2000-05-16 2007-05-30 博尔德生物技术公司 含游离半胱氨酸残基的蛋白重折叠的方法
AU2002223350A1 (en) 2000-12-01 2002-06-11 Eleanor N. Fish Cytokine receptor binding peptides
KR100459105B1 (ko) 2001-02-15 2004-12-03 선바이오(주) 변형된 인터페론-알파 2ａ 및 2ｂ, 그리고 이들과 ＰＥＧ유도체와의 배합체
MXPA05005178A (es) 2002-11-15 2005-07-22 Hoffmann La Roche Isomeros posicionales del interferon alfa 2a (ifn) pegilado con una porcion de polietilenglicol grande (peg).
WO2004046365A2 (en) 2002-11-18 2004-06-03 Maxygen, Inc. Interferon-alpha polypeptides and conjugates

Similar Documents

Publication Publication Date Title
JP2008507298A5 (enExample)
JP2008505985A5 (enExample)
RU2006145020A (ru) Полипептиды и конъюгаты интерферона-альфа
JP6297969B2 (ja) 部位特異的モノｐｅｇ化エキセンジン類似体およびその調製方法
CN101595122B (zh) 长效多肽及其生产和施用方法
CN103443122B (zh) 人胰岛素类似物及其酰化衍生物
EP3998077B1 (en) Cholix toxin-derived fusion molecules for oral delivery of biologically active cargo
JP2001520238A5 (enExample)
JP5907970B2 (ja) インターロイキン−２２のウイルス性肝炎の治療における応用
JP2006506097A5 (enExample)
RU2005118998A (ru) Полипептиды и конъюгаты альфа-интерферона
CN101255197A (zh) 血清白蛋白与白介素1受体拮抗剂的融合蛋白及应用
CN102558362A (zh) 一种用于治疗糖尿病的融合蛋白及其制备方法
CN103314010A (zh) h[Gly2]GLP-2的固相合成
WO1992004374A1 (fr) Nouveau polypeptide et medicament anti-vih prepare a partir de ce polypeptide
JP2008545393A5 (enExample)
JPWO2018234492A5 (enExample)
CN108864292B (zh) 一种干扰素重组融合蛋白及其应用
CN106279430B (zh) Exendin‑4类似物融合蛋白及其制备方法和用途
ES2290156T3 (es) Vector de expresion y secrecion del alfa interferon humano y procedimiento para producir alfa interferon humano empleando el anterior.
JPH0338600A (ja) Ｖｉｐ同族体
CN105085658B (zh) 一种白细胞介素29突变体及聚乙二醇衍生物
JP2011521648A5 (enExample)
ES2657788T3 (es) Proteínas fusionadas de interferón alfa 5 con otra citocina y un proceso de producción de las mismas
US20100184653A1 (en) Derivates of Polyethylene Glycol Modified Thymosin Alpha 1